腺 病毒 科
( |
|
门: | |
纲: | |
见 |
型 態
[编辑]遺傳 物質
[编辑]分類
[编辑]人類 腺 病毒 (Human adenovirus 简称:HAd)約 有 57種 血清 型 ,佔兒童 5%到 10%及大多數 成年 人的 上 呼吸 道 感染 的 成因 ;- 豬腺
病毒 (PAV)有 5種 血清 型 ; 羊 腺 病毒 (OAV)有 6種 血清 型 ;牛 腺 病毒 (BAV)分 為 兩個 族 群 。
鳥類 腺 病毒 屬 Atadenovirus- 禽類
腺 病毒 屬 Aviadenovirus - Ichtadenovirus
美 洲 白 鱘腺病毒 屬 Mastadenovirus唾液 酸 酶腺病毒 屬 Siadenovirus- Testadenovirus
生態
[编辑]人類 腺 病毒
[编辑]1953
臨床 症狀
[编辑]細胞 培養
[编辑]利用
[编辑]疫苗製造
[编辑]嬌生 COVID-19 疫苗
基 因 治療
[编辑]外部 連結
[编辑]
|
- ^
存 档副本 . [2020-12-18]. (原始 内容 存 档于2021-04-08). - ^ Adenoviridae. GBIF. [2023-03-14]. (
原始 内容 存 档于2023-03-14). - ^
存 档副本 . [2020-12-18]. (原始 内容 存 档于2021-04-08). - ^ Dhingra A, Hage E, Ganzenmueller T, Böttcher S, Hofmann J, Hamprecht K, et al. Molecular Evolution of Human Adenovirus (HAdV) Species C. Scientific Reports. January 2019, 9 (1): 1039. Bibcode:2019NatSR...9.1039D. PMC 6355881 . PMID 30705303. doi:10.1038/s41598-018-37249-4 .
- ^ Cross R. Adenoviral vectors are the new COVID-19 vaccine front-runners. Can they overcome their checkered past?. Chemical & Engineering News. 12 May 2020, 98 (19) [15 December 2020]. (
原始 内容 存 档于2020-08-23). - ^ Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. June 2020, 395 (10240): 1845–1854. PMC 7255193 . PMID 32450106. doi:10.1016/s0140-6736(20)31208-3.
- ^ It's not just Johnson & Johnson: China has a single-dose COVID-19 vaccine that's 65% effective. Fortune. [2021-02-11]. (
原始 内容 存 档于2021-05-15). - ^ Constable, Pamela; Hussain, Shaiq. Defying fears and skepticism, thousands in Pakistan volunteer for Chinese vaccine trials. Washington Post. [2021-01-01]. ISSN 0190-8286. (
原始 内容 存 档于2021-02-04). - ^ 9.0 9.1 China's CanSino Covid Vaccine Shows 65.7% Efficacy. Bloomberg.com. 2021-02-08 [2021-02-10]. (
原始 内容 存 档于2021-06-22). - ^ Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. August 2020, 396 (10249): 467–478. PMC 7445431 . PMID 32702298. doi:10.1016/S0140-6736(20)31604-4.
- ^ The Oxford/AstraZeneca COVID-19 vaccine: what you need to know. www.who.int. [2021-03-07]. (
原始 内容 存 档于2022-11-26) (英 语). - ^ Lee CS, Bishop ES, Zhang R, Yu X, Farina EM, Yan S, et al. Adenovirus-Mediated Gene Delivery: Potential Applications for Gene and Cell-Based Therapies in the New Era of Personalized Medicine. Genes & Diseases. June 2017, 4 (2): 43–63. PMC 5609467 . PMID 28944281. doi:10.1016/j.gendis.2017.04.001.
- ^ Thacker EE, Nakayama M, Smith BF, Bird RC, Muminova Z, Strong TV, et al. A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo. Vaccine. November 2009, 27 (50): 7116–24. PMC 2784276 . PMID 19786146. doi:10.1016/j.vaccine.2009.09.055.
- ^ Lewis TB, Glasgow JN, Harms AS, Standaert DG, Curiel DT. Fiber-modified adenovirus for central nervous system Parkinson's disease gene therapy. Viruses. 2014;6(8):3293-3310. Published 2014 Aug 21. doi:10.3390/v6083293. [2020-12-18]. (
原始 内容 存 档于2021-04-08). - ^ Lewis TB, Glasgow JN, Glandon AM, Curiel DT, Standaert DG. Transduction of brain dopamine neurons by adenoviral vectors is modulated by CAR expression: rationale for tropism modified vectors in PD gene therapy. PLoS One. 2010;5(9):e12672. Published 2010 Sep 17. doi:10.1371/journal.pone.0012672. [2020-12-18]. (
原始 内容 存 档于2021-04-08).